10-K: BeyondSpring Advances Plinabulin & TPD Pipeline Amidst Financial Headwinds

BeyondSpring Inc. reported a net loss of $14.2 million for 2025, while advancing its lead asset Plinabulin in NSCLC and its SEED Therapeutics' TPD platform into clinical studies.

Summary

• BeyondSpring reported a consolidated net loss of $14.2 million for the year ended December 31, 2025, an improvement from a $16.7 million net loss in 2024.
• The company's accumulated deficit reached $408.4 million as of December 31, 2025.
• Cash and cash equivalents from continuing operations increased to $7.8 million in 2025 from $2.9 million in 2024, with short-term investments also increasing to $4.8 million from nil.
• Research and development expenses rose to $4.4 million in 2025 from $2.6 million in 2024, primarily due to expanded drug manufacturing, data management for NSCLC studies, and research for Plinabulin combination therapies.
• General and administrative expenses decreased to $4.6 million in 2025 from $6.1 million in 2024, attributed to reduced headcount and lower professional service expenses.
• Discontinued operations, primarily SEED Therapeutics, reported a net loss of $5.5 million in 2025, an improvement from a $7.8 million loss in 2024.
• A gain of $7.0 million was recorded in 2025 from the sale of subsidiary interests in SEED.
• The DUBLIN-3 Phase 3 study for Plinabulin in secondand third-line NSCLC (EGFR wild type) demonstrated statistically significant and clinically meaningful overall survival benefit, doubling 2-year and 3-year OS rates, and an 82% reduction in grade 4 neutropenia.
• SEED Therapeutics' lead oncology asset, ST-01156, a novel RBM39 degrader, entered Phase 1 clinical studies in January 2026 and has received Orphan Drug and Rare Pediatric Disease designations from the FDA for Ewing sarcoma.
• BeyondSpring's direct and indirect ownership in SEED is expected to decrease from approximately 38.03% to 13.62% after the second and third closings of preferred share sales.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as moderately positive due to significant clinical trial success for Plinabulin in NSCLC and strategic advancements in the TPD platform, offset by ongoing financial losses, the FDA's Complete Response Letter for CIN, and the need for substantial future financing.

Positives

• Net loss decreased to $14.2 million in 2025 from $16.7 million in 2024, indicating improved financial performance.
• Cash and cash equivalents from continuing operations increased to $7.8 million in 2025 from $2.9 million in 2024, enhancing liquidity.
• The DUBLIN-3 Phase 3 study for Plinabulin in NSCLC met its primary endpoint, showing statistically significant and clinically meaningful overall survival benefit (HR=0.82) and doubling 2-year and 3-year OS rates.
• DUBLIN-3 also demonstrated an 82% relative reduction in grade 4 neutropenia in Cycle 1 Day 8 (p<0.0001), indicating a significant safety benefit.
• The Plinabulin/docetaxel combination in DUBLIN-3 was generally well-tolerated.
• SEED Therapeutics' lead oncology asset, ST-01156, a novel RBM39 degrader, successfully entered Phase 1 clinical studies in January 2026.
• ST-01156 received Orphan Drug and Rare Pediatric Disease designations from the FDA for Ewing sarcoma, potentially accelerating its development and market access.
• SEED has established research collaborations with Eli Lilly and Eisai, with potential milestone payments up to $780 million and $1.5 billion, respectively, validating its TPD platform.
• BeyondSpring recorded a $7.0 million gain on the sale of subsidiary interests in SEED in 2025.
• Plinabulin has been included in China's National Drug Priority Review List, potentially facilitating faster access to patients and reimbursement in China.
• General and administrative expenses decreased by $1.5 million in 2025, reflecting cost management efforts.

Negatives

• The company continues to incur significant net losses ($14.2 million in 2025) and has an accumulated deficit of $408.4 million, indicating ongoing financial challenges.
• The FDA issued a Complete Response Letter for Plinabulin in combination with G-CSF for the prevention of CIN in November 2021, requiring a second well-controlled trial, which significantly delays approval for this indication.
• The NDA submission for Plinabulin in CIN prevention was withdrawn from the NMPA in March 2023.
• Research and development expenses increased by $1.8 million in 2025, contributing to the overall operating loss.
• BeyondSpring's ownership in SEED Therapeutics is expected to decrease significantly from 38.03% to 13.62% after future closings of preferred share sales, diluting potential future upside from SEED.
• The company relies on BASF SE as the sole supplier of Kolliphor HS15, a critical stabilizing agent for Plinabulin, posing a supply chain risk.
• The company has a limited operating history and has not generated any revenue from product sales to date.
• There is significant uncertainty regarding the company's ability to obtain additional financing on acceptable terms to fund future operations.
• The CEO's salary was significantly reduced to $37,000 effective January 1, 2026, reflecting financial constraints.
• The company lost its foreign private issuer status as of January 1, 2025, which is expected to result in significant additional compliance costs.

Risks

• Limited operating history makes it difficult to evaluate current business and predict future performance.
• Anticipate continued net losses for the foreseeable future.
• Need to obtain additional financing to fund future operations; inability to do so may prevent development and commercialization.
• Substantial dependence on the success of Plinabulin; clinical trials may not be successful.
• FDA's Complete Response Letter for Plinabulin in CIN prevention requires a second well-controlled trial, significantly delaying or terminating development in this indication.
• Limited resources and capital necessitate prioritizing Plinabulin development; failure of Plinabulin-based candidates would adversely affect the business.
• Difficulties enrolling patients in clinical trials could delay or adversely affect development.
• Regulatory approval processes are lengthy, time-consuming, and unpredictable.
• Results from Phase 2/3 CIN trials and Phase 3 NSCLC trial may not be sufficiently robust for marketing application approval; additional trials may be required.
• Clinical trials conducted primarily in China (e.g., DUBLIN-3 with >80% Asian patients) may not be considered applicable to the U.S. patient population by the FDA, potentially requiring additional trials.
• Failure to achieve market acceptance by physicians, patients, and third-party payors, even if approved.
• Need to develop sales, marketing, and distribution capabilities, either internally or through third parties.
• Competition from pharmaceutical and biotechnology companies, including those with greater resources.
• Potential for earlier-than-expected generic competition for approved products.
• Inadequate reimbursement coverage for products could hinder commercialization.
• Changes in U.S. and Chinese regulations (e.g., Inflation Reduction Act, BIOSECURE Act, data security laws) could increase costs, limit pricing, or restrict operations.
• Limited intellectual property rights to Plinabulin inside China and reliance on commercialization partner Hengrui.
• Dependence on key executives and ability to attract/retain qualified personnel.
• Risks of doing business internationally, including geopolitical tensions (Russia-Ukraine, Middle East), economic instability, and regulatory changes.
• Reliance on third parties for clinical trials and manufacturing; failure of these parties could harm the business.
• Sole supplier risk for Kolliphor HS15, a key stabilizing agent for Plinabulin.
• Risk of product liability lawsuits.
• Fluctuations in exchange rates (RMB vs. USD) could result in foreign currency exchange losses.
• Investments are subject to risks that could result in losses.
• Risk of employees, contractors, or partners engaging in misconduct or improper activities.
• Failure to maintain an effective system of internal controls could adversely affect investor confidence.
• Potential for being classified as a Passive Foreign Investment Company (PFIC) for U.S. federal income tax purposes, leading to adverse tax consequences for U.S. shareholders.
• Uncertainties regarding interpretation and enforcement of Chinese laws, rules, and regulations.
• Chinese regulations on investments in offshore companies by Chinese residents may subject beneficial owners or subsidiaries to liability.
• Chinese regulations regarding employee equity incentive plans may lead to fines or sanctions.
• Reliance on dividends from PRC subsidiaries, which are subject to restrictions.
• Potential for being treated as a resident enterprise for Chinese tax purposes, leading to worldwide taxable income.
• Uncertainties with respect to indirect transfers of equity interests in Chinese resident enterprises.
• Restrictions on currency exchange in China may limit ability to utilize revenue effectively.
• Litigation and negative publicity surrounding China-based companies listed in the U.S. may increase regulatory scrutiny and impact share price.
• Risk of delisting from Nasdaq due to HFCAA if PCAOB cannot inspect auditors for two consecutive years (though current auditor is U.S.-based and inspected).
• Trading prices of ordinary shares are likely to be volatile.
• Sales of substantial amounts of ordinary shares could cause price decline.
• No expected dividends in the foreseeable future; reliance on price appreciation.
• Fewer shareholder rights under Cayman Islands law compared to U.S. law.
• Difficulties in protecting interests due to incorporation in Cayman Islands and directors residing outside U.S.
• Corporate actions substantially influenced by directors, executive officers, and principal shareholders.
• Increased costs and management time due to operating as a public company and loss of foreign private issuer status.
• Increased risk of securities class action litigation.

Future Outlook

The company plans to file an NDA for Plinabulin in NSCLC with the NMPA and initiate a confirmatory global Phase 3 study for secondand third-line non-squamous NSCLC (EGFR wild type after ICI progression). It also aims to partner with global pharmaceutical companies for Plinabulin's commercialization outside Greater China and maximize the value of SEED's TPD platform through additional partnerships and advancing its proprietary pipeline. The company anticipates needing substantial additional funding to support its operating activities, advance product candidates through clinical development, seek regulatory approval, and prepare for commercialization.

Management Comments

• "We believe that its unique mechanism supports the improved anti-cancer efficacy potential in combination with tumor antigen generators, including chemotherapy or radiation, with or without checkpoint inhibitors."
• "We plan to use our best efforts to file an NDA with the NMPA as soon as possible."
• "We plan to initiate a confirmatory global phase 3 study in secondand third-line non-squamous NSCLC with epidermal growth factor receptor (EGFR) wild type after progression on prior immune checkpoint inhibitors, based on productive discussion with US regulatory agency."
• "We believe SEED is an established leader in overcoming the significant scientific challenges to discovering molecular glue, which enables the development of a new class of drugs with the potential to treat many previously untreatable medical conditions through the targeting of disease-causing proteins that are resistant to inhibition with traditional drug discovery methods."
• "We continue to explore strategic options in the United States and globally to support the execution of our business plan and to maximize shareholder value. These options may include licensing and partnership arrangements, a sale of the Company or its assets, equity or debt financing, or a combination of the above."
• "We anticipate that our current financial resources will allow us to meet our operational expenses and capital expenditures in the next 12 months after the date of this Annual Report on Form 10-K."

Industry Context

StockSavvy.ai notes that the biopharmaceutical industry is highly competitive, characterized by extensive R&D and significant regulatory hurdles. The oncology market, particularly for non-small cell lung cancer (NSCLC) patients who have progressed on immune checkpoint inhibitors (ICIs), represents a substantial unmet medical need, as evidenced by the failure of 11 recent Phase 3 studies to surpass docetaxel in overall survival. The global market for PD-1/PD-L1 inhibitors, valued at approximately $60 billion in 2025 and projected to reach $135.55 billion by 2031, highlights the significant commercial opportunity in this space. BeyondSpring's focus on Plinabulin's unique mechanism of dendritic cell maturation and its investment in SEED Therapeutics' Targeted Protein Degradation (TPD) platform position it within innovative approaches to address these complex challenges, potentially offering differentiated therapeutic benefits compared to existing standards of care.

Comparison to Industry Standards

• Plinabulin's DUBLIN-3 study demonstrated a doubling of 2-year and 3-year overall survival (OS) rates and an 82% reduction in grade 4 neutropenia compared to docetaxel alone in secondand third-line NSCLC. This is a significant improvement over docetaxel, a drug approved over 25 years ago, which offers modest OS benefits (around 9 months) and a high severe neutropenia rate (over 40%).
• In the investigator-initiated Phase 2 study (Study 303) of Plinabulin + Pembrolizumab + Docetaxel for NSCLC patients who progressed on PD-1/PD-L1 inhibitors, a disease control rate of 85.1% and a 12-month OS rate of 79.3% were observed. This compares favorably to the TROPION Lung-01 Phase 3 study in a similar patient population, which reported an objective response rate (ORR) of 12.8% and median progression-free survival (mPFS) of 3.7 months with docetaxel.
• The investigator-initiated Phase 1 study of Plinabulin + pegfilgrastim in multiple myeloma patients undergoing autologous hematopoietic cell transplantation (AHCT) showed only 10% experienced non-engraftment related neutropenic fevers or febrile neutropenia (FN), significantly lower than the historical rate of 60% FN with standard of care.
• SEED Therapeutics' molecular glue technology has been featured as a leading Targeted Protein Degradation (TPD) company in Nature Review articles, indicating strong scientific recognition and competitive standing in this emerging drug discovery field.

Management Changes

Corporate Governance

Legal Proceedings

• An arbitration proceeding initiated by Jiangsu Hengrui Pharmaceuticals Co., Ltd. regarding a commercialization and co-development agreement was concluded on January 10, 2024, with the arbitral tribunal denying all claims made by Hengrui.
• BeyondSpring US is currently under federal audit for the 2023 tax year by the Internal Revenue Service (IRS).

Related Party Transactions

• The JKNM Living Trust, for which Board Member Jiangwen Majeti is the trustee, purchased 117,647 shares of SEED's Series A-3 Preferred Shares for $500,000 in September 2025, on the same terms as those offered to third-party investors.
• Mr. Linqing Jia, spouse of CEO Dr. Lan Huang and co-founder, is employed as the president of Wanchunbulin and received compensation exceeding $120,000 in 2023.
• Dr. Lan Huang's stepdaughter is employed as a vice president at BeyondSpring US, and her spouse is employed as a senior director at BeyondSpring US. Each received compensation exceeding $120,000 in both 2024 and 2025.

Stakeholder Impact

• **Shareholders**: Potential for increased value from successful clinical trials (Plinabulin in NSCLC) and strategic advancements in the SEED TPD platform. However, ongoing net losses, the need for substantial future financing, and the dilution of SEED ownership (from 38.03% to expected 13.62%) pose risks to investment value. Share price volatility is also a concern.
• **Employees**: An organizational streamlining initiative in January 2022 included a reduction in force. Executive compensation adjustments, such as the CEO's salary reduction and the CSO's salary increase, directly impact key personnel.
• **Customers/Patients**: The advancement of Plinabulin in NSCLC and the SEED pipeline offers potential for new, more effective therapies for various cancers and improved prevention of chemotherapy-induced neutropenia, addressing high unmet medical needs.
• **Partners (Hengrui, Eli Lilly, Eisai)**: Continued collaboration and potential for significant milestone payments and royalties from successful drug development and commercialization, reinforcing the value of these partnerships.
• **Creditors**: Ongoing net losses and the stated need for additional financing in the medium to long term indicate potential risks to the company's ability to meet future debt obligations, although current financial resources are anticipated to cover the next 12 months.

Next Steps

• File an NDA with the NMPA for Plinabulin in NSCLC as soon as possible.
• Initiate a confirmatory global Phase 3 study for Plinabulin + docetaxel vs. docetaxel alone in secondand third-line non-squamous NSCLC (EGFR wild type after progression on prior immune checkpoint inhibitors).
• Work closely with the FDA to consider the possible future clinical and regulatory pathway for the CIN prevention indication.
• Seek co-development and commercialization partners for Plinabulin in the U.S. and the rest of the world.
• Advance SEED's proprietary product pipeline and seek additional partnerships to expand its TPD platform into several therapeutic areas.
• Complete the second and third closings of the sale of SEED Series A-1 Preferred Shares (expected in 2026 and by December 15, 2026, respectively).
• Continue preclinical studies and clinical development of other immune-oncology product candidates (BPI-002, BPI-003, BPI-004).
• Monitor legal and regulatory developments regarding scientific data interpretation in China, particularly concerning clinical study data sharing.

Key Dates

Recommendation

StockSavvy.ai recommends a 'hold' position. While the positive Phase 3 results for Plinabulin in NSCLC and the strategic advancements in the SEED TPD platform are significant catalysts, the company faces substantial financial challenges, including ongoing net losses, a critical need for additional financing, and the FDA's Complete Response Letter for the CIN indication. The dilution of SEED ownership also reduces future upside for BeyondSpring shareholders. Investors should await further clarity on regulatory approvals, commercialization strategies, and successful capital raises before considering a stronger position.

Keywords

Biopharmaceutical, Oncology, Plinabulin, NSCLC, CIN, Targeted Protein Degradation, TPD, Molecular Glue, SEED Therapeutics, Clinical Trials, FDA, NMPA, Eli Lilly, Eisai, Cancer Therapy, Drug Development, BYSI, Nasdaq